Work

Figure 5 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes

Year: 2025
Type: other
Abstract: Luminal-B CTC phenotype and persistent PSMA expression are associated with poor response to 177Lu–PSMA-617. A, Clinical benefit rate (the best radiographic response of stable disease, partial response, or complete response) for 177Lu–PSMA-617 in patients with favorable pretreatment CTC phenotypes (Low_CTC, LP, and LumA) vs. pretreatment LumB phenotype. B, Proportion of pretreatment LumB vs. favorable CTC phenotypes for patients with and without 177Lu–PSMA-617 early progression (disease progression within the first three cycles/18 weeks of treatment). C, Baseline CTC FOLH1 (PSMA) gene expression for LumB (n = 8) vs. favorable CTC phenotypes (n = 29). Kaplan–Meier plot for (D) radiographic progression-free survival (rPFS) and (E) OS illustrates decreased rPFS and OS after starting 177Lu–PSMA-617 for patients with the pretreatment LumB CTC phenotype. F, Longitudinal evaluation of consensus AR/luminal and neuroendocrine pathway scores during 177Lu–PSMA-617 treatment. Patient 818 (left) represents an example of a patient with early progression on 177Lu–PSMA-617 who demonstrated a rapid increase in NE score and decrease in AR score on treatment. Patient 978 (right) illustrates a patient with a longer duration of response who also shows an increased NE score and decreased AR score at the time of disease progression.
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4410047380
Cites:
Cited by:
Related to: 10